Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Michael Chapman(Dartmouth College), William Wilson(Cancer Research UK), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Selina J Chavda(University College London), Ruth M. de Tute(St James's University Hospital), María Cuadrado(University College London), Reuben Benjamin(King's College London)
Cited by 25
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605